Latest News

Research examines links between ‘long COVID’ and ME/CFS


 

Will COVID-19 unleash a new wave of ME/CFS patients?

Much of the session at the virtual meeting was devoted to ongoing studies. For example, Leonard Jason, PhD, of the Center for Community Research at DePaul University, Chicago, described a prospective study launched in 2014 that looked at risk factors for developing ME/CFS in college students who contracted infectious mononucleosis as a result of Epstein-Barr virus. Now, his team is also following students from the same cohort who develop COVID-19.

Because the study included collection of baseline biological samples, the results could help reveal predisposing factors associated with long-term illness from either virus.

Another project, funded by the Open Medicine Foundation, will follow patients who are discharged from the ICU following severe COVID-19 illness. Blood, urine, and cerebrospinal fluid will be collected from those with persistent symptoms at 6 months, along with questionnaire data. At 18-24 months, those who continue to report symptoms will undergo more intensive evaluation using genomics, metabolomics, and proteomics.

“We’re taking advantage of this horrible situation, hoping to understand how a serious viral infection might lead to ME/CFS,” said lead investigator Ronald Tompkins, MD, ScD, chief medical officer at the Open Medicine Foundation and a faculty member at Harvard Medical School, Boston. The results, he said, “might give us insight into potential drug targets or biomarkers useful for prevention and treatment strategies.”

Meanwhile, Sadie Whittaker, PhD, head of the Solve ME/CFS initiative, described her organization’s new plan to use their registry to prospectively track the impact of COVID-19 on people with ME/CFS.

She noted that they’ve also teamed up with “long-COVID” communities including Body Politic. “Our goal is to form a coalition to study together or at least harmonize data … and understand what’s going on through the power of bigger sample sizes,” Dr. Whittaker said.

None of the speakers disclosed relevant financial relationships.

A version of this article originally appeared on Medscape.com.

Pages

Recommended Reading

Deaths, despair tied to drug dependence are accelerating amid COVID-19
Federal Practitioner
Does metformin reduce risk for death in COVID-19?
Federal Practitioner
COVID-19 impact: Less chemo, immune checkpoint inhibitors, and steroids
Federal Practitioner
COVID-19 and the myth of the super doctor
Federal Practitioner
PPE shortage could last years without strategic plan, experts warn
Federal Practitioner
FDA authorizes new saliva COVID-19 test
Federal Practitioner
Only 40% of residents said training prepped them for COVID-19
Federal Practitioner
Severe obesity ups risk for death in younger men with COVID-19
Federal Practitioner
Swab, spit, stay home? College coronavirus testing plans are all over the map
Federal Practitioner
FDA authorizes convalescent plasma for COVID-19
Federal Practitioner